- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
, July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST ) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.
1 million declined 6.9%; organic net sales declined 5.9%.
Reported-diluted EPS of $1.51 , compared to $2.06 in the same period last year.
Adjusted-diluted EPS of $1.52 , compared to $2.11 in the same period last year.
The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion , compared to a prior range of $3.
000 billion to $3.025 billion . The Company is updating full-year 2024 adjusted-diluted EPS guidance to a range of $6.
35 to $6.65 , compared to a prior range of $7.63 to $7.
88 . "The second quarter continued to be impacted by an elevated level of customer destocking," said Eric M. Green , President, Chief Executive Officer and Chair of the Board.
"While the results were below our expectations, we were encouraged to see our second-quarter revenues increase sequentially. Our outlook anticipates that revenues in the second half of the year will be stronger than the first half. Based on our confirmed order book and ongoing customer conversations, we remain confident in a return to organic growth in the fourth quarter and as we move into 2025.
We see considerable growth opportunity in the markets we s.